Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Motzer
    Motzer
  3. Brennan
    Brennan
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Vickers
    Vickers
  7. Russo
    Russo
  8. Shaha
    Shaha
  9. Eastham
    Eastham
  10. Scardino
    Scardino

Groups

  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)
  7. Sloan Kettering Institute Faculty (612)
  8. Department of Pathology and Laboratory Medicine (555)
  9. Epidemiology and Biostatistics (494)
  10. Center for Hematologic Malignancies (437)
Search Within
Formats
  1. Journal Article (3530)
  2. Meeting Abstract (684)
  3. Review (200)
  4. Book Section (107)
  5. Conference Paper (94)
  6. Editorial (91)
  7. Research Letter (35)
  8. Guidelines (28)
  9. Correspondence (25)
  10. Miscellaneous (5)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)

More Groups

People
  1. Harry Herr (92)
  2. Robert Motzer (87)
  3. Murray Brennan (86)
  4. Jatin Shah (77)
  5. Andrew Vickers (74)
  6. Samuel Danishefsky (74)

More People

Years
  1. 2025 (147)
  2. 2024 (192)
  3. 2023 (261)
  4. 2022 (186)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1461)
  2. Journal of Surgical Oncology (376)
  3. BJU International (338)
  4. Hematological Oncology (199)
  5. Histopathology (158)
  6. EMBO Journal (132)

More Publications

Results (4802)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer–specific mortality
    Journal Article

    Bitterman, D. S.; Chen, M. H.; Wu, J.; Renshaw, A. A.; Loffredo, M.; Kantoff, P. W.; Small, E. J.; D'Amico, A. V.
    Cancer (2021)

    Fulltext@MSK | Save
  • The prevalence and predictors of penile pain in men with Peyronie's disease
    Journal Article

    Flores, J. M.; Salter, C. A.; Nascimento, B.; Terrier, J. E.; Taniguchi, H.; Bernie, H. L.; Miranda, E.; Jenkins, L.; Schofield, E.; Mulhall, J. P.
    Sexual Medicine (2021)

    Fulltext@MSK | Save
  • Role of maintenance rituximab after first‐line bendamustine + rituximab or R‐CHOP in patients with mantle cell lymphoma from a large US real‐world cohort
    Meeting Abstract

    Wang, M.; Salles, G.; Kumar, A.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Martin, P.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • SARS‐CoV‐2 infection in 50 patients with primary CNS lymphoma: Presentation, effects on tumor treatment and outcome in a series of the International PCNSL Collaborative Group
    Meeting Abstract

    Ferreri, A. J. M.; Steffanoni, S.; Calimeri, T.; Laurenge, A.; Fox, C. P.; Soussain, C.; Grommes, C.; Sassone, M. C.; Touat, M.; Boot, J.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Key genetic and molecular aberrations identified in both adult and EBV‐positive Burkitt lymphoma patients
    Meeting Abstract

    Orem, J.; Martin, M. R.; Mbulaiteye, S. M.; Mullighan, C. G.; Mungall, A. J.; Mungall, K.; Namirembe, C.; Noy, A.; Petrello, H.; Ogwang, M. D.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Predictive value of quantitative (18)F‐FDG‐PET‐CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Moskowitz, A. J.; Kersten, M. J.; Moskowitz, C. H.; Eertink, J. J.; van de Brug, T.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Real‐world treatment patterns and outcomes of 3455 previously untreated mantle cell lymphoma patients in US routine clinical practice
    Meeting Abstract

    Kumar, A.; Martin, P.; Wang, M.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Extended follow‐up from the phase 2 CheckMate 436 study
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Estimation of long‐term survival with tafasitamab + lenalidomide (LEN) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Salles, G.; Goswami, B.; Bagnardi, V.; Dey, D.; Winderlich, M.; Ambarkhane, S.; Huang, D.; Nowakowski, G. S.
    Hematological Oncology (2021)

    Fulltext@MSK | Save